ArticleCardio-oncology (London, England)2026

Clinical utility of the HFA-ICOS risk tool in real-world HER2-positive breast cancer patients receiving therapy.

Lama Alfehaid et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.